Abstract: The present invention relates to the medicine, in particular, to a new drug effective for the treatment of diseases associated with aberrant interferon gamma signaling, such as Sjögren's syndrome, dermatomyositis, systemic lupus erythematosus, or systemic sclerosis; for the treatment of patients suffering from cough; and for the treatment of disorders in steroid-resistant patients, such as asthma, rheumatoid arthritis, systemic lupus erythematosus, and gastrointestinal diseases, by administering a compound 1-(2-(1H-imidazol-4-yl)ethyl) piperidin-2,6-dione The invention provides the creation of a new effective drug for overcoming steroid resistance.
Type:
Application
Filed:
November 22, 2019
Publication date:
November 17, 2022
Applicant:
"CHEMIMMUNE THERAPEUTICS" LIMITED LIABILITY COMPANY
Abstract: The invention relates to medicine and concerns the treatment of diseases related to the aberrant activity of fractalkine and monocyte chemoattractant proteins 1-4 (CCL2, CCL7, CCL8, CCL13), preferably the treatment of pain, fever, pneumonia, bronchitis, bronchiolitis, alveolitis, rheumatoid arthritis, psoriasis and other diseases, using the compound 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione or a pharmaceutically acceptable salt or solvate thereof The present invention also relates to pharmaceutical compositions that contain a therapeutically effective amount of the claimed compound according to the invention. The present compound and pharmaceutically acceptable salts thereof are highly effective in inhibiting the activity of the glutaminyl cyclase enzyme, which is involved in particular in processes of post-translational modification of the above-mentioned cytokines.
Type:
Application
Filed:
March 6, 2018
Publication date:
June 18, 2020
Applicant:
"CHEMIMMUNE THERAPEUTICS" LIMITED LIABILITY COMPANY
Inventors:
Vladimir Evgenievich NEBOLSIN, Anastasia Vladimirovna RYDLOVSKAYA